Tandem Diabetes Care's new PayGo option is starting to reshape how insulin pumps reach patients, according to analysts at RBC Capital Markets. In the first full quarter since the program's launch, roughly 10% of Tandem's US sales ran through pharmacy benefit channels, and formulary coverage—the list of insurance plans that cover the product—has already reached 45%.
PayGo is a zero-upfront payment model that routes sales through pharmacy benefits rather than the traditional approach of buying a pump outright. For patients, that means lower initial costs, which could make insulin pumps more accessible. For Tandem, it's a strategic bet that could expand its customer base and change the revenue mix.
What the numbers show
RBC's analysis of Tandem's second-quarter results suggests demand is holding up even if the headline financials didn't impress. The company shipped a record 22,000 pumps, and new patient starts rose more than 20% from the prior quarter. That growth is notable because it comes as Tandem transitions to a model that may shift when and how revenue is recognized.
The pharmacy channel is a key part of that shift. Instead of a one-time device sale, PayGo likely generates recurring revenue through ongoing supply and service fees. That could smooth out revenue over time, but it also means the financial picture may look different quarter to quarter.
Formulary coverage at 45% is a significant milestone. It means nearly half of insured patients could have access to PayGo through their pharmacy benefits, which is often a more convenient and cost-effective route than durable medical equipment coverage. RBC's estimate suggests the program is gaining traction with insurers and pharmacy benefit managers.
Why PayGo matters
Insulin pumps have traditionally been sold as durable medical equipment, with patients paying a large upfront cost and then dealing with insurance reimbursements. That model can be a barrier for many people, especially those with high deductibles or limited savings. PayGo's zero-upfront structure removes that hurdle, potentially opening the market to a broader group of patients.
For Tandem, the shift is about more than just convenience. By moving more sales through pharmacy channels, the company can tap into a different reimbursement ecosystem that may be more predictable and faster. It also aligns with a broader industry trend toward subscription-like models in medical devices, where the upfront cost is replaced by ongoing payments.
Investors are watching this transition closely because it could affect Tandem's revenue recognition, cash flow, and profitability. In the short term, a shift to pharmacy channels might compress margins or delay revenue, but if it drives higher patient adoption, the long-term payoff could be substantial.
What it means for investors
For everyday investors, the key takeaway is that Tandem is making a deliberate strategic pivot. The record pump shipments and strong patient start growth suggest the underlying demand is there, but the financial impact of PayGo is still unfolding. RBC's data points—10% of sales through pharmacy and 45% formulary coverage—are early indicators of how quickly the model is catching on.
Investors should also consider the competitive landscape. Tandem competes with other insulin pump makers like Medtronic and Insulet, and a successful PayGo rollout could give it an edge in attracting new patients. However, the transition also carries risks, including potential reimbursement delays or lower margins on pharmacy-channel sales.
As with any company undergoing a business model shift, the next few quarters will be telling. If PayGo continues to gain formulary coverage and pharmacy sales grow, it could become a meaningful driver of Tandem's growth. If adoption stalls, the company may need to adjust its strategy.
For now, RBC's assessment suggests the early returns are encouraging. The math is starting to change, and investors will be watching to see if that trend continues.
